Solana (SOL) is seeing sustained institutional demand, with 11 consecutive days of ETF purchases reducing available supply. This dynamic is fueling expectations of a possible push toward $300, while affecting institutional managers, corporate treasuries and product/compliance teams responsible for crypto exposure.
According to data, spot Solana ETFs in the U.S. have recorded $350,47M in cumulative net inflows in less than two weeks, with Bitwise’s BSOL ETF concentrating $331,74M and Grayscale’s GSOL contributing $18,72M. The REX‑Osprey SSK ETF added $3,4M, raising its assets to $198,5M. These daily flows suggest a structured rotation of institutional capital into SOL via ETFs, a vehicle that enables exposure without direct custody.
Corporate treasuries are also accumulating SOL as part of reserve strategies. Forward Industries announced a private placement of $1,65B to initiate a Solana treasury strategy and executed a purchase of $1,58B in SOL. Helius Medical Technologies reported financing of more than $500M for its Solana treasury vehicle and disclosed the purchase of 760.190 SOL for $175,6M at an average price of $231 per token.
At least six strategic entities are accumulating more than 15.000.000 SOL, contributing to a shift of liquidity from exchanges to long‑term reserves. The thesis combines persistent ETF inflows, treasury accumulation and expanding derivatives access.
Regulatory, derivatives and technical outlook
CME Group has scheduled the launch of options on Solana futures for October 13, 2025, adding hedging tools and institutional liquidity. Bloomberg places the probability of approval of spot SOL ETPs around 90%, while prediction market Polymarket raises it to 99%, according to cited market sources. These developments expand access and risk management capabilities for larger allocators.
Technical analyses highlight an initial target near $300, supported by a cup‑and‑handle base and a double bottom near the demand zone at $155, alongside an RSI forming higher lows and a MACD suggesting a bullish crossover. The report’s reference price is positioned near $156, framing support/resistance levels for the scenario.
The next operational milestone is CME’s options rollout on October 13, 2025. The combination of persistent ETF inflows, corporate treasury purchases and new derivative tools will determine whether buying pressure drives a sustainable breakout toward $300 or results in a liquidity‑driven adjustment and volatility.
